Bacterial efflux pump

Scandion Oncology (Scandion), an innovative drug efflux pump inhibition company using biomodulation capabilities to revert drug resistance, today announced topline data for the CORIST part 3 continuation trial and that the company established the maximum tolerated dose (MTD) of SCO-101 in combination with the chemotherapy FOLFIRI in colorectal cancer patients. The established MTD for a 4-Days schedule of SCO-101 in combination with FOLFIRI was found to be 250 mg daily SCO-101, 50% irinotecan and 100% Leucovorin and 5-FU. “We are pleased to have reached the primary endpoint of this continuation trial, establishing the MTD of SCO-101 in combination with FOLFIRI,” said Lars Damstrup, CMO of Scandion Oncology. “We now have the recommended dose that we may use in the next steps of the development of SCO-101.” The continuation study of CORIST part 3 included 3 patients. The dose of SCO-101 was the same as in the previous cohort, i.e., 250 mg per day for four days. Folinic acid and 5-FU were administered as per standard of care. The dose of irinotecan was increased from 50% to 65% of the normal standard dose. Of the 3 patients, 2 experienced a dose-limiting toxicity of neutropenia, which was expected based on previous data. No new safety signals were detected. Final data in the CORIST part 3 continuation trial is expected in the first half of 2025. For further information please contact: Johnny Stilou, CFO Phone: +45 2960 3532 E-mail: jos@scandiononcology.com This information is information that Scandion Oncology A/S is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above on August 16, 2024, at 07.00 CET. About Scandion Oncology Scandion Oncology (Scandion) is a clinical-stage biotech company using an innovative drug efflux pump inhibition technique with biomodulation capabilities on ABCG2 and UGT1A1 targets to revert drug resistance. Drug resistance remains a massive problem in cancer treatment and in the development of new medicines. Scandion’s lead compound SCO-101 is currently studying metastatic colorectal cancer (mCRC) in its Phase 2 CORIST trial, while the PANTAX Phase 1 program is developing SCO-101 for pancreatic cancer. Scandion is based in Copenhagen and is listed on Nasdaq First North Growth Market Sweden (ticker: SCOL). Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market. This information is information that Scandion Oncology is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-08-16 07:00 CEST.